Vasomotor Symptoms Associated with Menopause

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause [Phase 1, Phase 2]

  AbCellera Biologics is evaluating ABCL635 in a Phase 1/2 study for vasomotor symptoms of menopause; the trial is currently recruiting.

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

  An ongoing observational study sponsored by Bayer investigates the burden of vasomotor symptoms in menopausal women and patterns of treatmen…

• CLINICAL_TRIALS trial_result · 2026-02-12
  Clinical Trial Update: A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause [Phase 3]

  Phase 3 trial evaluating elinzanetant for vasomotor symptoms (hot flashes) due to menopause has completed. Results have been posted.

• CLINICAL_TRIALS trial_result · 2025-12-01
  Clinical Trial Update: A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause [Phase 3]

  Phase 3 study to evaluate the efficacy and safety of Elinzanetant for menopause-related vasomotor symptoms (hot flashes) over 52 weeks. Resu…

• FDA approval · 2024-04-22
  FDA Approved: ESTRADIOL — Original Application (Solaris Pharma Corporation)

  FDA approves Solaris Pharma Corporation's Estradiol as an original application (generic) product for estrogen replacement therapy.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2023-05-23
  FDA Approved: DIVIGEL — Supplemental Application (Vertical Pharmaceuticals, LLC)

  FDA approved a supplemental application for Divigel (estradiol) by Vertical Pharmaceuticals, LLC to modify its labeling.

• FDA approval · 2015-09-25
  FDA Approved: DUAVEE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

  The FDA approved a supplemental application for DUAVEE (conjugated estrogens/bazedoxifene) from Wyeth Pharmaceuticals LLC (Pfizer) to suppor…

• FDA label_change · 2013-04-24
  FDA Approved: VIVELLE-DOT — Supplemental Application (Sandoz Inc)

  FDA approved a supplemental application for VIVELLE-DOT (estradiol) from Sandoz Inc, resulting in updated labeling.